Which Patients with Anxiety Symptoms Benefit Most from Treatment with Bryophyllum pinnatum? A Secondary Analysis of a Prospective, Single-Arm Study
Complementary Medicine Research · 30.04.2026 · 33 (3) · 191-198
DOI: 10.1159/000552252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Complementary Medicine Research, online erschienen am 30.04.2026. Verfasst von Tiffany Huber und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Department, Klinik Arlesheim, Arlesheim, Switzerland. Hauptthemen laut MEDLINE: Anxiety, Kalanchoe, Phytotherapy, Plant Extracts. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Bryophyllum spp. preparations are frequently used in integrative settings. A recent study observed a reduction in anxiety symptoms among a heterogeneous group of psychiatric/psychosomatic patients after 2 weeks of treatment with Bryophyllum 50% chewable tablets. This secondary analysis aims to identify variables associated with a stronger reduction in anxiety symptoms.
Methods
Fifty-four patients with anxiety symptoms were recruited from the waiting list for inpatient care at the “Klinik Arlesheim,” Department of Psychiatry and Psychosomatics, and treated with Bryophyllum 50% chewable tablets (3 × 2 per day; Weleda AG, Arlesheim, Switzerland). The primary outcome was a change in anxiety symptoms, measured by the Beck Anxiety Inventory (BAI) after 2 weeks of treatment relative to baseline (ΔBAI). Comparisons were made across subgroups using one-way ANOVA. Multivariate analyses (MVA) were conducted to assess the relative importance of various independent variables, including the depression scale (PHQ-9).
Results
BAI score decreased by an average of 5 points (from 27.4 ± 12.0 to 22.4 ± 12.1; p < 0.001, n = 54). ΔBAI decreased progressively across age quartiles and increased with baseline BAI scores (BAIbl). Patients on benzodiazepines showed less improvement compared to those who were not. MVA indicated that ΔBAI was significantly associated with age (inversely) and with BAIbl (proportionally), after adjusting for other relevant variables. When BAIbl was excluded from the MVA model, a nonsignificant association was observed between ΔBAI and PHQ-9.
Conclusion
Due to the uncontrolled single-arm design, our findings are exploratory and do not permit causal inferences. Nevertheless, this explorative analysis suggests that younger age and more severe anxiety symptoms were associated with greater reductions in anxiety symptom burden during treatment with Bryophyllum 50% chewable tablets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Department, Klinik Arlesheim, Arlesheim, Switzerland.
- Clinical Research Department, Society for Cancer Research, Arlesheim, Switzerland.
- Sleep Medicine, Klinik Arlesheim, Arlesheim, Switzerland.
- Research Institute Havelhöhe, Berlin, Germany.
- Institute for Integrative Medicine, University Witten/Herdecke, Herdecke, Germany.
- Department of Psychiatry and Psychosomatics, Klinik Arlesheim, Arlesheim, Switzerland.
Zitieren
APA
Huber, T., Krüerke, D., Kröz, M., Schlemmer, M., & Simões-Wüst, A. P. (2026). Which Patients with Anxiety Symptoms Benefit Most from Treatment with Bryophyllum pinnatum? A Secondary Analysis of a Prospective, Single-Arm Study. Complementary Medicine Research, 33(3), 191-198. https://doi.org/10.1159/000552252
Vancouver
Huber T, Krüerke D, Kröz M, Schlemmer M, Simões-Wüst AP. Which Patients with Anxiety Symptoms Benefit Most from Treatment with Bryophyllum pinnatum? A Secondary Analysis of a Prospective, Single-Arm Study. Complementary Medicine Research. 2026;33(3):191-198. doi:10.1159/000552252
BibTeX
@article{Huber2026,
author = {Huber, Tiffany and Krüerke, Daniel and Kröz, Matthias and Schlemmer, Markus and Simões-Wüst, Ana Paula},
title = {Which Patients with Anxiety Symptoms Benefit Most from Treatment with Bryophyllum pinnatum? A Secondary Analysis of a Prospective, Single-Arm Study},
journal = {Complementary Medicine Research},
year = {2026},
volume = {33},
number = {3},
pages = {191--198},
doi = {10.1159/000552252}
}
EUVIMED